Hyderabad Pharma City
Hyderabad Pharma City — rebranded Green Pharma City — is the corridor’s flagship under-construction node and, at 19,000+ acres, the largest pharma-specific cluster planned in India. Sited across three mandals of Ranga Reddy district, ~25 km from the Outer Ring Road, it carries National Investment and Manufacturing Zone status (granted December 2019) and is implemented through TSIIC via the SPV Hyderabad Pharma City Limited.
It is in Phase 1 (9,212 ac of a phased 19,333 ac), with roughly 12,000 acres acquired and construction commenced in targeted zones. Commitments stand at ₹11,100 cr across 17 MoUs (6 earlier plus 11 named at BioAsia 2025) for 22,300+ jobs, against a far larger government target of ₹64,000 cr and 1.66 lakh jobs. No tenant is operational yet — Phase 1 industries are targeted to begin in 2026.
The named pipeline is strong on paper: Bharat Biotech, Biological E, Granules, Jubilant, Aragen, Sai Life Sciences and others signed MoUs at BioAsia 2025 (₹5,445 cr, 9,800 jobs), with MSD adding a global technology centre. But the only two formal land allottees identified — Amazon Data Services (48 ac) and Adani Defence — are both non-pharma and have been formally questioned by the CAG as deviations from the node’s mandate.
Companies & commitments
| Company | Sector | Commitment |
|---|---|---|
| Bharat Biotech | Vaccines & biotech | MoU at BioAsia 2025 — part of the 11-company ₹5,445 cr / 9,800-job pool [V] |
| Biological E | Vaccines & biologics | MoU at BioAsia 2025 — part of the ₹5,445 cr pool [V] |
| Granules, Virchow, Virupaksha | Pharmaceuticals | MoUs at BioAsia 2025 — part of the ₹5,445 cr pool [V] |
| Jubilant, Aragen, Sai Life Sciences | Life sciences & CDMO | MoUs at BioAsia 2025 — part of the ₹5,445 cr pool [V] |
| Orbicular, Aizant, Vimta | Pharma R&D, drug delivery & clinical testing | MoUs at BioAsia 2025 — part of the ₹5,445 cr pool [V] |
| MSD (Merck Sharp & Dohme) | Global technology centre | Separate BioAsia 2025 announcement (a 12th distinct company); investment not specified [V] |
| Amazon Data Services India | Data centre (non-pharma) | 48 ac allotted — questioned by the CAG as a deviation from the pharma mandate [V/D] |
| Adani Defence Systems & Technologies | Defence systems (non-pharma) | Land allotted — flagged by the CAG as an undue benefit (deviation from pharma mandate) [V/D] |
Industries coming up
Infrastructure & connectivity
- 19,000–19,333 ac (~77 km²) across Kandukur, Yacharam and Kadthal mandals — the largest pharma-specific cluster planned in India, far above Genome Valley’s ~2,000 ac. Phased: Phase 1 (2023–26) 9,212 ac, Phase 2 (2026–29) ~5,000 ac for biotech/biosimilars/vaccines, Phase 3 (2029+) for smart technologies and Centres of Excellence.
- ~12,000 of 19,300 ac acquired as of Aug 2024 (a CAG report flagged ~10,238 ac as non-contiguous); estimated project cost ~₹19,098 cr with a ₹1,550 cr land-acquisition budget. Market land price surged from under ₹50 lakh/acre to ~₹5 cr/acre after announcement; official TGIIC land price and plot sizes not found in sources.
- Master-plan zones cover bulk-drug manufacturing, formulations, an R&D hub, ancillary industries, residential townships and green buffer corridors; percentage land-use breakdown not found. Tabreed is contracted for Asia’s largest district-cooling concession (~$200m, 125,000 RT). Environmental clearance status was not found in sources and Hyderabad Pharma City does not appear on the NICDC EC-granted list.
- ~25 km from the Outer Ring Road and ~29 km from Rajiv Gandhi International Airport; part of a planned set of pharma villages between the ORR and the proposed Regional Ring Road. No dedicated freight corridor or port linkage documented; the water source and power allocation — both critical for water-intensive pharma — were not found in sources.
Incentives & land: NIMZ status (single-window clearance and infrastructure support) plus the Telangana Next-Gen Life Sciences Policy 2026–30, unveiled at Davos in January 2026: 100% stamp- and transfer-duty reimbursement, 25% land-cost reimbursement (capped at ₹10 lakh) in state parks, a power subsidy and 100% net SGST reimbursement for five years from commercial production. A ‘Green Pharma City’ net-zero mandate (district cooling, environmental corridors) frames the build-out.
India’s largest pharma cluster, by design
Hyderabad Pharma City is conceived as an extension and consolidation of Hyderabad’s existing dominance in pharmaceuticals — the region already accounts for over 40% of India’s bulk-drug production, and adjacent Genome Valley hosts 200+ companies and roughly a third of global vaccine output. The NIMZ designation positions the park as a project of national importance with single-window clearance and infrastructure support.
The master plan splits the 19,333 acres into bulk-drug, formulations, R&D, ancillary, residential and green-buffer zones across three phases through 2029 and beyond, with Phase 2 earmarked for biotech, biosimilars and vaccines. A Tabreed district-cooling concession and a ‘Green Pharma City’ net-zero framing are intended to differentiate it on environmental performance — a pointed response to Hyderabad’s legacy of pharmaceutical effluent pollution.
MoUs, allottees and the CAG flags
At BioAsia 2025 the Telangana government signed 11 MoUs worth ₹5,445 cr for 9,800 jobs — Granules, Orbicular, Aizant, Biological E, Virchow, Virupaksha, Jubilant, Vimta, Aragen, Bharat Biotech and Sai Life Sciences — and MSD separately announced a global technology centre. Cumulative MoU commitments reach ₹11,100 cr for 22,300+ jobs across 17 companies. These are intent: no formal land-allotment orders for the BioAsia signatories were found.
The only two formal land allotments identified are non-pharma and contentious. The CAG questioned a 48-acre allotment to Amazon Data Services and an allotment to Adani Defence Systems as undue benefits and deviations from the park’s pharmaceutical mandate under NIMZ, alongside wider findings of TSIIC fund diversion in 2018–2022. No pharmaceutical facility had commenced operations as of mid-2026.
Risks & open questions
Execution is the central risk: converting ~12,000 acquired (and partly non-contiguous) acres into serviced industrial plots, against documented farmer-displacement disputes and legal hurdles over land-use change. The government’s ₹64,000 cr / 1.66 lakh-job target dwarfs the ₹11,100 cr of signed MoUs, and the CAG flagged delays severe enough that Phase 1 — originally 2017–2020 — was incomplete well into the decade.
Several load-bearing details are absent from sources: the environmental clearance status (no SEAC/SEIAA order found, and the node is missing from the NICDC EC list), the water source and allocation for a water-intensive sector, the power allocation and tariff, export-port and DFC connectivity, and the Centre:State equity split in the SPV. Phase 1 completion timing also differs between the project portal (2026) and other sources (late 2025 initial segments).
Timeline
- Mar 2018Project announced by K. T. Rama Rao
- Dec 2019NIMZ status granted by the Government of India
- 2023Phase 1 construction commences in targeted zones
- Aug 2024~12,000 ac acquired; market land price ~₹5 cr/acre
- Feb 202511 MoUs signed at BioAsia 2025 (₹5,445 cr); total commitments ₹11,100 cr
- Jan 2026Next-Gen Life Sciences Policy 2026–30 unveiled at Davos
- 2026Phase 1 industries targeted to commence operations
Sources
- BioSpectrum India — 11 MoUs for Green Pharma City ↗
- Times of India — CAG questions Amazon land allotment ↗
- The New Indian Express — TSIIC fund diversion / Adani Defence (CAG) ↗
- Business Standard (PTI) — Next-Gen Life Sciences Policy ↗
- PIB — NIMZ / integrated pharma cluster ↗
- Pharma City Hyderabad — projects & master plan ↗
- Wikipedia — Hyderabad Pharma City ↗